Invest New Drugs 2009,29(1):182–8.PubMedP5091 in vivo CrossRef 33. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D: Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 122(1):1–7. 34. Miles DW, Romieu G, Dieras V, Chen D, Duenne A, Robert N: Meta-analysis of patients (PTS) 65 years from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy SCH727965 concentration as treatment for Metastatic Breast Cancer (MBC). In European Society for Medical Oncology (ESMO): 2010; Milan (ITALY). Annals of Oncology; 2010:viii96-viii121. (#278PD) 35. Miles DW, Romieu G, Dieras V, Chen D, Duenne

A, O’Shaughnessy J: Meta-analysis of patients (PTS) previously treated with Taxanes from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy as treatment for Metastatic Breast Cancer (MBC). In European Society for Medical Oncology (ESMO): 2010; Milan (ITALY). Annals of Oncology; 2010:viii96-viii121. (#279PD) https://www.selleckchem.com/products/GDC-0941.html 36. Straus SE: Individualizing treatment decisions. The likelihood of being helped or harmed. Evaluation & the health professions 2002,25(2):210–224. 37. Barrios C, Liu M, Lee S, Vanlemmens L, Ferrero

J, Tabei T, Pivot X, Iwata H, Aogi K, Brickman M, et al.: Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). Cancer Res 2009, 69:46. (24_MeetingAbstracts)CrossRef 38. Baselga J, Grupo Espanol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores S, Roche H, Costa F, Getulio Martins buy Hydroxychloroquine Segalla J, Pinczowski H, Ma Ciruelos E, Cabral Filho S, Gomez

P, Van Eyll B: SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). Cancer Res 2009, 69:45. (24_MeetingAbstracts)CrossRef 39. Gradishar W, Kaklamani V, Prasad Sahoo T, Lokanatha D, Raina V, Bondarde S, Jain M: A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). Cancer Res 2009, 69:44. (24_MeetingAbstracts)CrossRef 40. Mackey J, Hurvitz S, Crown J, Forbes J, Roche H, Pinter T, Eiermann W, Kennedy M, Priou F, Provencher L, et al.: CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC). Cancer Res 2009, 69:47. (24_MeetingAbstracts)CrossRef 41. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29(6):632–638. 42.